1. Introduction {#sec1-marinedrugs-16-00049}
===============

Octocorals of the genus *Leptogorgia* biosynthesize highly oxygenated diterpenoids based on the cembrane skeleton: (a) furanocembranolides into which a γ-lactone subunit is embedded; (b) 1,4-diketocembranoids produced by oxidative cleavage of the furan ring; and (c) *nor*-1,4-diketocembranolides that lack the C-18 isoprenic methyl group \[[@B1-marinedrugs-16-00049],[@B2-marinedrugs-16-00049]\].

It has been suggested that activation of pancreatic beta-cell proliferation is a strategy to maintain functional beta-cell mass in diabetes mellitus \[[@B3-marinedrugs-16-00049]\]. Regarding this, we have shown that furanocembranoids such as epoxypukalide, pukalide, *Z*-deoxypukalide and leptolide improve beta-cell proliferation \[[@B4-marinedrugs-16-00049],[@B5-marinedrugs-16-00049],[@B6-marinedrugs-16-00049]\]. This prompted us to study a new extract of *Leptogorgia* sp. collected by SCUBA diving off Aleta (Panama), from which compounds **1**--**9** were obtained after flash chromatography followed by HPLC ([Figure 1](#marinedrugs-16-00049-f001){ref-type="fig"}). The unusual halogenated compounds **1** and **2**, together with the known *Z*-desoxypukalide (**6**) \[[@B1-marinedrugs-16-00049]\] and rubifolide (**7**) \[[@B7-marinedrugs-16-00049]\] belong to the furanocembranolide structural class. The remaining six compounds typify three different subclasses that involve several types of rearrangements from a furanocembranolide precursor: (a) **3**, **4** and the previously isolated epoxylophodione (**9**) \[[@B8-marinedrugs-16-00049]\] are 1,4-diketocembranolides, **4** being the only haloderivative of the genus *Leptogorgia* of this subclass; (b) compound **5** is the first *seco*-furanocembranolide isolated from genus *Leptogorgia*, which showed a similar ring scission pattern to *seco*-bipinnatin J, the only *seco*-derivative \[[@B9-marinedrugs-16-00049]\] isolated from *Pseudopterogorgia*; and (c) scabrolide D (**8**) \[[@B10-marinedrugs-16-00049]\] is a *nor*-1,4-diketocembranolide which lacks the C-18 isoprenic methyl group.

2. Results {#sec2-marinedrugs-16-00049}
==========

Compound **1** was obtained as an oil whose EIMS spectrum showed peaks at *m*/*z* \[M − 1\]^+^ 409/411, with relative intensities suggesting one chlorine atom. These peaks correspond to the molecular formula C~20~H~23~ClO~7~ (HREIMS) (*m*/*z* 409.1041 \[M − 1\]^+^, calcd. for C~20~H~22~^35^ClO~7~ 409.1054). The diterpenic nature of **1** is corroborated by the ^13^C NMR spectrum (in [Supplementary Materials](#app1-marinedrugs-16-00049){ref-type="app"}), which displayed correlations in the HSQC spectrum indicative of seven quaternary carbons, six methines, six methylenes and one methyl ([Table 1](#marinedrugs-16-00049-t001){ref-type="table"}). Absorptions for a hydroxyl group at 3476 cm^−1^ and carbonyl groups at 1776 and 1676 cm^−1^ were observed in the IR spectrum.

Notable ^1^H and ^13^C NMR signals are: an aldehyde group \[δ~H-18~ 9.89 (1H, s), δ~C-18~ 184.7\], a trisubstituted furane ring \[δ~H-5~ 6.70 (1H, s), δ~C-5~ 106.5; δ~C-3~ 161.3; δ~C-6~ 156.0; δ~C-4~ 123.4\], a α,β-epoxy-γ-lactone ring \[δ~H-11~ 3.73 (1H, s), δ~C-11~ 62.9; δ~C-20~ 172.1; δ~H-10~ 4.85 (1H, dd, *J* = 5.2, 11.3 Hz), δ~C-10~ 74.3 and δ~C-12~ 60.6\] and a chloromethylene \[δ~H-17~ 4.18 (2H, br s) y δ~C-17~ 46.6\].

Connectivity information obtained from COSY, HSQC and HMBC experiments unambiguously determined the planar structure of compound **1** as a furanocembranolide, containing a C-18 oxidized to aldehyde, a vicinal diol at C-7--C-8, a C-10--C-20 α,β-epoxy-γ-lactone moiety and a chloroisopropenyl group at C-1.

^1^H-^1^H-COSY experiments established two spin systems: H~2~-2--H~2~-13 (fragment **I**) and H~2~-9--H-10 (fragment **II**) ([Figure 2](#marinedrugs-16-00049-f002){ref-type="fig"}). The HMBC correlations H~2~-16/C-17, C-15, C-1 and H~2~-17/C-16, C-15, C-1 locate a chloroisopropenyl group at C-1 of fragment **I**, whereas the correlations H~3~-19/C-7, C-8 and C-9 allowed us lengthen fragment **II** by adding a vicinal dihydroxyl moiety bonded to C-9. The north end of both fragments **II** and **I** are connected together by insertion of a furane ring, in agreement with the HMBC correlations H-5/C-3, C-4, C-6 and H~2~-2 with C-4. An epoxy lactone binds the southern ends of fragments **I** and **II** between C-13 and C-10, as deduced from the HMBC correlations H-10/C-11, C-12, C-20; H~2~-13/C-20, C-11, C-12 and H~2~-14 with C-12. Thus, the structure of **1**, with nine degrees of unsaturation, has been established.

Compound **2** was obtained as an oil whose EIMS spectrum showed a molecular ion at *m*/*z* \[M\]^+^ 394/396, with an isotopic pattern for a chlorine atom in the molecular formula C~20~H~23~ClO~6~ (HREIMS) (*m*/*z* 394.1181 \[M\]^+^, calcd. for C~20~H~23~^35^ClO~6~ 394.1183). The ^13^C NMR spectrum and correlations in the HSQC spectrum indicated seven quaternary carbons, six methines, six methylenes and one methyl ([Table 1](#marinedrugs-16-00049-t001){ref-type="table"}). Absorptions for a hydroxyl group at 3558 cm^−1^ and carbonyl group at 1747 cm^−1^ were observed in its IR spectrum.

^1^H and ^13^C NMR data resemble those of **1**. The principal differences lie in the chemical shifts of H-7, H~2~-9, C-9 and C-19, which were: δ~H-7~ 4.59 (1H, s), δ~H-9~ 1.89 (1H, m); 2.59 (1H, dd); δ~C-9~ 43.0 and δ~C-19~ 19.6, compared with those of **1** ([Table 1](#marinedrugs-16-00049-t001){ref-type="table"}). These shift values suggested that compounds **1** and **2** differ in the configuration of C-7 and C-8. Also, their molecular formulas diverge by 16 amu of oxygen. This suggests that the γ-lactone ring system is devoid of the epoxide ring on **2**. This absence is confirmed by the new signals observed in the ^1^H and ^13^C NMR spectra for a proton (δ~H-11~ 5.86 (1H, s)) of a disubstituted olefin (δ~C-11~ 148.6; δ~C-12~ 136.2). Thus, the structure of **2** with nine degrees of unsaturation was established as shown in [Figure 1](#marinedrugs-16-00049-f001){ref-type="fig"} by COSY, HSQC and HMBC experiments.

The relative configurations of compounds **1** and **2** were ascertained by NOESY experiments, molecular mechanics \[[@B11-marinedrugs-16-00049]\], chemical shift studies and comparison of their spectroscopic data with those of previously described cembranoids, leptodiol \[[@B1-marinedrugs-16-00049]\], lophodiol A \[[@B12-marinedrugs-16-00049]\] and sinumaximol B \[[@B13-marinedrugs-16-00049]\] ([Figure 3](#marinedrugs-16-00049-f003){ref-type="fig"}).

In compound **1**, the observed NOEs of H-5 with H-7 and H~3~-19, together with those of H-7 with H~3~-19 suggested that the adjacent hydroxyl groups at C-7--C-8 should be in a *cis* relationship. In compound **2**, the observed NOEs of H~3~-19 with H-5 and H-10 indicate that these protons and Me-19 must be on same side of the molecule, whereas the NOEs of H~3~-19 with H-9a and of H-7 with H-9b indicates that H-7 and Me-19, so the vicinal diols on C-7--C-8, have a *trans-*relationship. Therefore, the relative configuration of C-8 is opposite to that on compound **1**.

The configurations of C-7--C-8 vicinal diols were corroborated by comparison of the ^1^H and ^13^C NMR chemical shifts around the diol moiety C-7--C-8 of compounds **1** and **2** with those of the related diols leptodiol, lophodiol A and sinumaximol B, shown in [Table 2](#marinedrugs-16-00049-t002){ref-type="table"}. The chemical shifts of C-19 and H-7 of compounds **1** and **2** present strong differences (Δδ~C-19~ = 2.8 ppm and Δδ~H-7~ = 0.7). The chemical shifts of C-19 and H-7 of leptodiol (δ~C-19~ 22.7; δ~H-7~ 5.12) and lophodiol A (δ~C-19~ 22.7; δ~H-7~ 5.24), both with the C-7--C-8 diols in an α-*cis*-relationship, are very similar to those of compound **1**. Whereas the chemical shifts of C-19 and H-7 of sinumaximol B (δ~C-19~ 19.8; δ~H-7~ 4.52), whose C-7--C-8 diols show a *trans-*relationship, present strong differences (upfield Δδ~C-19~ ≈ 2.6 ppm and downfield Δδ~H-7~ ≈ 0.8) which are very similar to those presented by compound **2** in comparison to compound **1**.

In compound **1**, a striking ^1^H NMR signal is the singlet observed for H-11 (δ 3.73, s) due to the roughly 90° dihedral angle formed between H-10 and H-11. This results in a small *J*~H-10,\ H-11~ that confirms the relative configuration of C-10 and C-11 as represented in the energetically favourable conformation shown in [Figure 3](#marinedrugs-16-00049-f003){ref-type="fig"}.

Finally, in compound **1**, the relative configuration of C-1 was secured by the NOESY correlation of H-13b with H-1 and H-13a with H-11, as shown in the 3D model in [Figure 3](#marinedrugs-16-00049-f003){ref-type="fig"}. In compound **2**, the observed NOEs of H-1 with H-2a and H-14a, as well as of H-14a with H-11 and of H-2b with H-14b, indicate that the isopropenyl group of **2** is situated on the alpha side of the molecule. Therefore, both compounds belong to the furanocembranolide of the α-series and their relative configurations are: 1*R*\*, 7*S*\*, 8*S*\*, 10*S*\*, 11*S*\* and 12*S*\* for compound **1** and 1*R*\*, 7*S*\*, 8*R*\* and 10*S*\* for compound **2**.

Compound **3** was obtained as an oil whose EIMS spectrum showed a peak at *m*/*z* 362 \[M\]^+^, which corresponds to the molecular formula C~20~H~26~O~6~ (HREIMS) (*m*/*z* 362.1737 \[M\]^+^, calcd. for C~20~H~26~O~6~ 362.1729). These data are in agreement with the ^13^C NMR spectrum, which displayed correlations in the HSQC spectrum indicative of seven quaternary carbons, four methines, six methylenes and three methyls. Absorptions for a hydroxyl group at 3475 cm^−1^ and carbonyl groups at 1751, 1721 and 1701 cm^−1^ were observed in their IR spectrum. According to the degree of unsaturation given by the ^13^C NMR data, **3** must be a tricyclic compound.

In the ^1^H and ^13^C NMR experiments ([Table 3](#marinedrugs-16-00049-t003){ref-type="table"}), signals were found for: α,β-unsaturated-γ-lactone ring \[δ~H-11~ 6.76 (1H, s), δ~C-11~ 155.9; δ~C-20~ 170.6; δ~C-10~ 90.5\]; isopropenyl group \[δ~H-16~ 4.68 (1H, br s), δ~H-16~ 4.70 (1H, br s); δ~C-16~ 109.7\] and \[δ~H-17~ 1.69 (3H, s); δ~C-17~ 20.9\]; methyl group on a quaternary carbon bonded to oxygen \[δ~H-19~ 1.37 (CH~3~, s) and δ~C-8~ 74.3\]; oximethine proton bonded to a secondary carbon \[δ~H-5~ 3.31 (1H, d, 10.4 Hz) and δ~C-5~ 60.8\] and two carbonyls \[δ~C-3~ 215.4 and δ~C-6~ 203.5\].

^1^H-^1^H-COSY experiments established two spin systems: H~2~-2--H~2~-13 (fragment **I**) and H~3~-18--H-5 (fragment **II**) ([Figure 4](#marinedrugs-16-00049-f004){ref-type="fig"}). The HMBC correlations of H~2~-16/C-1, C-17 and H~3~-17/C-16, C-15, C-1 locates the isopropenyl group at C-1 in fragment **I**, whereas the HMBC correlations of H~2~-2 and H~3~-18 with C-3 connects fragments **I** and **II** through C-3. The HMBC correlations H~3~-19/ C-7, C-8, C-9, along with those of H-5 and H~2~-7 with C-6, allowed us to extend fragment **II** by connecting it with substructure **III** through C-6. Both ends of the fragment **I** and substructure **III** (C-6--C-9) are connected by inserting an α,β-unsaturated γ-lactone bonded to C-13 and C-9, respectively, due to the HMBC correlations H~2~-13/C-20, C-11, C-12 and those of H-11/C-10 and H~2~-9/C-10, C-11. The quaternary feature of C-10 comes from the oxygen linkage between C-5 and C-10 supported by an HMBC correlation of H-5 with C-10. Therefore, the tricyclic structure of **3** has been established as depicted in [Figure 4](#marinedrugs-16-00049-f004){ref-type="fig"}.

Compound **4** was obtained as an oil whose EIMS spectrum showed peaks at *m*/*z* 396/398 \[M\]^+^, which correspond to the formula C~20~H~25~ClO~6~ (HREIMS) (*m*/*z* 396.1324 \[M\]^+^, calcd. for C~20~H~25~O~6~^35^Cl, 396.1340). Considering the HSQC correlations, signals observed in the ^13^C NMR spectrum indicate seven quaternary carbons, four methines, seven methylenes and two methyls. Absorptions for a hydroxyl group at 3420 cm^−1^ and carbonyl groups at 1727, 1690 and 1647 cm^−1^ were observed in their IR spectrum.

^1^H and ^13^C NMR data ([Table 3](#marinedrugs-16-00049-t003){ref-type="table"}) resemble those of **3**. The molecular formula of **4** showed that one proton of **3** is substituted by a chlorine atom in **4**. Its corresponding data from both ^1^H and ^13^C NMR reveal that the substitution is situated on the isopropenyl appendage, where the methyl group of **3** changed to chloromethylene in **4**. This substitution was confirmed by the fragment (*m*/*z* 321.1335 \[M − C~3~H~4~Cl\]^+^, calcd. for C~17~H~21~O~6~, 321.1338) observed in HREIMS. The planar structure of **4** was confirmed as the 17-chloro derivative of compound **3** by COSY, HSQC and HMBC experiments.

NOESY experiments, studies of coupling constants and molecular mechanics calculations suggest that **3** and **4** have the same relative stereochemistry ([Figure 1](#marinedrugs-16-00049-f001){ref-type="fig"}). In both compounds, NOEs were observed for H-5 with H-9a and H-11 and for H~3~-19 with H-9a and H-9b, defining a relative configuration for C-5 and C-10 and establishing H~3~-19 on C-8 in a *pseudo*-equatorial disposition and therefore coplanar to H-5. Also, the large coupling constants of H-5 (*J* = 10.4 Hz) in **3** and H-5 (*J* = 10.3 Hz) in **4** indicate that H-5 and H-4 are *trans*-diaxial, as the observed NOE between H-5 and H~3~-18 corroborates. Finally, the NOE observed between H-11 and H-1 places the isopropenyl group on the opposite side to the Me-18. Therefore, the overall relative configuration for **3** and **4** should be 1*R*\*, 4*R*\*, 5*S*\*, 8*R*\* and 10*S*\*.

Compound **5** was obtained as an oil with an EIMS spectrum peak at *m*/*z* 388 \[M\]^+^, which corresponds to the molecular formula C~21~H~24~O~7~ (HREIMS) (*m*/*z* 388.1524 \[M\]^+^, calcd. for C~21~H~24~O~7~, 388.1522). These data are in agreement with the ^13^C NMR spectrum, which displayed correlations in the HSQC spectrum indicating eight quaternary carbons, five methines, five methylenes and three methyls ([Table 3](#marinedrugs-16-00049-t003){ref-type="table"}). Absorptions for carbonyl groups at 1655, 1650 and 1638 cm^−1^ were noted in the IR spectrum.

In addition to the ^1^H and ^13^C NMR data registered for an isopropenyl group, a furan ring and a α,β-unsaturated-γ-lactone, other notable key signals were detected for the following functional groups: aldehyde \[δ~H-7~ 9.54 (1H, s), δ~C-7~ 177.1\]; methyl ketone \[δ~H-19~ 2.21 (3H, s), δ~C-8~ 204.3\] and methyl ester \[δ~H-21~ 3.86 (3H, s), δ~C-18~ 162.9\]. The 21 carbon atoms given by the molecular formula suggested that the isoprenic methyl group C-18 of a regular furanocembranolide is oxidized to a methyl ester and that the methyl-ketone and the aldehyde might come from the oxidative cleavage of the C-7--C-8 bond. According to the connectivity information from experiments COSY, HSQC and HMBC, compound **5** should be a *seco*-furanocembranolide.

^1^H-^1^H-COSY experiments established two spin systems: H~2~-2--H~2~-13 (fragment **I**) and H~2~-9--H-10 (fragment **II**) ([Figure 5](#marinedrugs-16-00049-f005){ref-type="fig"}). The HMBC correlations of H~2~-16/C-1, C-17 and H~3~-17/C-16, C-15, C-1 locate the isopropenyl group at C-1 of fragment **I** and also those of H-5/C-3, C-4, C-6 and H~2~-2 with C-3 connected fragment **I** at the furan ring. The HMBC correlations of H~2~-13/C-11, C-12, C-20 and H-11/C-10 and H~2~-9/C-11 showed that fragments **I** and **II** are linked through an α,β-unsaturated-γ-lactone. HMBC correlations of H~3~-19/C-8, C-9 allowed us to place the methyl-ketone. Finally, the aldehyde must be located at C-6, in good agreement with the chemical shift observed for the aldehyde group of *seco*-bipinnatin J (δ~H-7~ 9.52 (1H, s), δ~C-7~ 177.5), the only *seco*-derivative \[[@B9-marinedrugs-16-00049]\] isolated from *Pseudopterogorgia*, which showed the same scission pattern.

Compound **5** is the first *seco*-furanocembranolide isolated from genus *Leptogorgia*. *Z*-deoxypukalide \[[@B1-marinedrugs-16-00049]\], also isolated in this work, can be considered a biogenetic precursor of **5** by oxidative cleavage of the corresponding Δ^7,8^. Since *Z*-deoxypukalide belongs to the α-cembranolide series, we assign the same relative configurations 1*R*\*, 10*S*\* to **5**.

It should be expected that compounds **1**--**5** belong to the same enantiomeric series as *Z*-deoxypukalide, (**6**) whose absolute configuration we have previously determined using an NMR-based method using Pirkle's reagent \[[@B1-marinedrugs-16-00049]\].

Activation of Pancreatic Beta-Cell Proliferation
------------------------------------------------

Several strategies have been proposed to recover functional beta-cell mass loss in diabetes mellitus onset; one of them is to activate beta-cell proliferation \[[@B3-marinedrugs-16-00049]\]. In previous work, we showed that furanocembranolides such as epoxypukalide, pukalide, *Z*-deoxypukalide and leptolide augment beta-cell proliferation \[[@B4-marinedrugs-16-00049],[@B5-marinedrugs-16-00049],[@B6-marinedrugs-16-00049]\]. In order to acquire detailed knowledge of the proliferation effect induced by furanocembranolides, compounds **1**, **2** and rubifolide (**7**) were used to treat synchronized INS-1 cells and proliferation was then measured. INS-1 cells were preincubated with 0.1 μM of each product and proliferation was measured by BrdU incorporation ([Table 4](#marinedrugs-16-00049-t004){ref-type="table"}), showing a 2--3-fold increase in proliferation. Although it is difficult to reach a conclusion regarding the functional groups that could modulate this proliferation activity, these results also support chloro-furanocembranolides being potential activators of pancreatic beta-cell proliferation.

Furthermore, synchronized INS-1 cells were treated with the *nor*-cembranolide, scabrolide D (**8**), ([Table 4](#marinedrugs-16-00049-t004){ref-type="table"}), showing a 2.8 ± 0.69-fold change above untreated cells (1.0). We therefore consider it of interest in searching for compounds of the furanocembranolide and *nor*-1,4-diketocembranolide families, in order to develop a new class of antidiabetic agents.

3. Experimental Section {#sec3-marinedrugs-16-00049}
=======================

3.1. General Experimental Procedures {#sec3dot1-marinedrugs-16-00049}
------------------------------------

Optical rotations were measured on a Perkin-Elmer model 343 Plus polarimeter (Perkin-Elmer, Rodgau, Germany) using a Na lamp at 20 °C. IR spectra were recorded on a Perkin-Elmer 1650/FTIR spectrometer (Perkin-Elmer, Rodgau, Germany). ^1^H NMR and ^13^C NMR, HSQC, HMBC and COSY spectra were measured employing a Bruker AMX 500 instrument (Bruker, Karlsruhe, Germany) operating at 500 MHz for ^1^H NMR and at 125 MHz for ^13^C NMR. All ^13^C and ^1^H NMR spectra were internally referenced to the residual solvent signal (CDCl~3~: δ~C~ 77.0 ppm, δ~H~ 7.25 ppm). Two-dimensional NMR spectra were obtained using the standard Bruker software (TOpSpin 2.1, Bruker, Karlsruhe, Germany). The EIMS data were obtained on a Waters Vg-Micromass spectrometer (Waters, Manchester, UK) model Zab 2F. HPLC separations were performed on an Agilent 1200 Series Quaternary LC system (Agilent Technologies, Waldbronn, Germany) apparatus equipped with a UV detector (DAD G1315D, Agilent Technologies, Waldbronn, Germany) and an Ascentis^®^ C18 semi-preparative column (5 μm, 25 cm × 21.2 mm, Supelco, Bellefonte, PA, USA) eluted with CH~3~CN-H~2~O mixtures. Size-exclusion chromatography used Sephadex LH-20 as stationary phase and hexane-MeOH-CH~2~Cl~2~ (3:1:1) as solvent system. The spray reagent used to develop TLC plates was H~2~SO~4~-H~2~O-AcOH (1:4:20).

3.2. Collection, Extraction and Isolation {#sec3dot2-marinedrugs-16-00049}
-----------------------------------------

*Leptogorgia* sp. was collected by SCUBA diving off Aleta (Panama) at −10 m. A voucher specimen has been deposited at the Smithsonian Tropical Research Institute (Panama City, Panama) with code 200708. Specimens of *Leptogorgia* sp. (458.3 g) were extracted with acetone at room temperature and were concentrated to give a dark gum (10.1 g). C-18 reversed-phase flash chromatography of the crude extract gave fractions 4 (290.4 mg; 2:3 H~2~O/MeOH) and 5 (1119.1 mg; 1:4 H~2~O/MeOH) containing cembranolides, as indicated by their ^1^H NMR spectra. Fraction 4 was further chromatographed by molecular exclusion LH-20 to give two sub-fractions of interest, 4~1~ (39.4 mg) and 4~5~ (18.6 mg). C-18 reversed-phase HPLC of 4~1~ using a gradient from H~2~O-CH~3~CN (7:3) to CH~3~CN (100%) afforded compound **1** (1.3 mg, t~R~ 61 min) and scabrolide D (**8**) (6.5 mg, t~R~ 64 min). From sub-fraction 4~5~, compounds **2** (5.4 mg; t~R~ 101.5 min) and **4** (0.5 mg; t~R~ 83 min) were separated after C-18 reversed-phase HPLC using a gradient from H~2~O-CH~3~CN (7:3) to CH~3~CN (100%). Fraction 5 was chromatographed by molecular exclusion LH-20 to give five sub-fractions of interest: 5~1~ (87.6 m), 5~2~ (89.5 mg), 5~3~ (82.9 mg), 5~4~ (59.1 mg) and 5~5~ (50.3 mg). All these fractions were chromatographed separately by C-18 reversed-phase HPLC using a gradient from H~2~O-CH~3~CN (7:3) to CH~3~CN (100%), to afford compounds **3** (1.6 mg; t~R~ 83.1 min), **5** (2.1 mg; t~R~ 52.3 min), *Z*-deoxypukalide (**6**) (5.7 mg; t~R~ 111.2 min), rubifolide (**7**) (6.0 mg; t~R~ 74 min) and epoxylophodione (**9**) (0.4 mg; t~R~ 82.3 min).

Compound **1**: Colourless oil; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{20}$ −20.7 (*c* 0.03, CH~2~Cl~2~); IR (film) ν~max~ 3476, 2932, 1776, 1676 cm^−1^; ^1^H (500 MHz, CDCl~3~) δ 1.35 (3H, s, H-19), 1.42 (1H, m, H-14a), 1.45 (1H, m, H-13a), 1.51 (1H, m, H-9), 1.87 (1H, dd, *J* = 5.2, 15.0 Hz, H-9), 2.04 (1H, m, H-14b), 2.44 (1H, dd, *J* = 11.5, 14.7 Hz, H-13b), 3.15 (2H, m, H-2), 3.39 (1H, m, H-1), 3.73 (1H, s, H-11), 4.18 (2H, br s, H-17), 4.85 (1H, dd, *J* = 5.2, 11.3 Hz, H-10), 5.29 (1H, s, H-7), 5.37 (1H, s, H-16a), 5.47 (1H, s, H-16b), 6.70 (1H, s, H-5), 9.89 (1H, s, H-18); ^13^C NMR (125 MHz CDCl~3~) δ 22.4 (CH~3~, C-19), 22.5 (CH~2~, C-13), 30.4 (CH~2~, C-14), 32.9 (CH~2~, C-2), 37.6 (CH, C-1), 40.5 (CH~2~, C-9), 46.6 (CH~2~, C-17), 60.6 (C, C-12), 62.9 (CH, C-11), 74.0 (CH, C-7), 74.3 (C, C-8), 74.3 (CH, C-10), 106.5 (CH, C-5), 118.0 (CH~2~, C-16), 123.4 (C, C-4), 144.2 (C, C-15), 156.0 (C, C-6), 161.3 (C, C-3), 172.0 (C, C-20), 184.7 (CH, C-18); EIMS *m*/*z* 409/411 \[M − 1\]^+^, 395/397 \[M − CH~3~\]^+^, 393/395 \[M − OH\]^+^, 355 \[M − C~3~H~4~Cl\]^+^; HREIMS *m*/*z* \[M − 1\]^+^ 409.1041 (calcd. for C~20~H~22~^35^ClO~7~ 409.1054), 411.1027 (calcd. for C~20~H~22~^37^ClO~7~, 411.1025), 395.0887 (calcd. for C~19~H~20~^35^ClO~7~, 395.0898), 395.1069 (calcd. for C~20~H~22~^37^ClO~6~, 395.1075).

Compound **2**: Colourless oil; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{20}$ −11.0 (*c* 0.10, CH~2~Cl~2~); IR (film) ν~max~ 3558, 2935, 1747, 1674 cm^−1^; ^1^H (500 MHz, CDCl~3~) δ 1.41 (3H, s, H-19), 1.60 (1H, ddd, *J* = 2.8, 2.8, 15.1 Hz, H-14a), 1.89 (1H, dd, *J* = 11.7, 14.8 Hz, H-9b), 2.02 (1H, m, H-14b), 2.14 (1H, m, H-13a), 2.35 (1H, ddd, *J* = 2.8, 11.9, 15.1 Hz, H-13b), 2.46 (1H, dddd, *J* = 2.2, 2.5, 9.5, 11.7 Hz, H-1), 2.59 (1H, dd, *J* = 4.1, 14.8 Hz, H-9a), 2.97 (1H, dd, *J* = 2.5, 14.8 Hz, H-2a), 3.19 (1H, dd, *J* = 11.9, 15.1 Hz, H-2b), 4.12 (2H, br s, H-17), 4.59 (1H, s, H-7), 4.97 (1H, m, H-10), 5.19 (1H, s, H-16), 5.36 (1H, s, H-16), 5.86 (1H, s, H-11), 6.80 (1H, s, H-5), 9.97 (1H, s, H-18); ^13^C NMR (125 MHz, CDCl~3~) δ 19.6 (CH~3~, C-19), 21.7 (CH~2~, C-13), 30.2 (CH~2~, C-14), 32.7 (CH~2~, C-2), 39.7 (CH, C-1), 43.0 (CH~2~, C-9), 47.2 (CH~2~, C-17), 73.6 (C, C-8), 75.6 (CH, C-7), 78.4 (CH, C-10), 106.5 (CH, C-5), 117.0 (CH~2~, C-16), 122.7 (C, C-4), 136.2 (C, C-12), 146.9 (C, C-15), 148.6 (CH, C-11), 154.3 (C, C-6), 162.1 (C, C-3), 173.5 (C, C-20), 184.3 (CH, C-18); EIMS *m*/*z* 394/396 \[M\]^+^, 377/379 \[M − OH\]^+^; HREIMS *m*/*z* \[M\]^+^ 394.1181 (calcd. for C~20~H~23~O~6~^35^Cl, 394.1183), 396.1162 (calcd. for C~20~H~23~O~6~^37^Cl, 396.1154), 377.1146 (calcd. for C~20~H~22~O~5~^35^Cl, 377.1156), 379.1133 (calcd. for C~20~H~22~O~5~^37^Cl, 379.1126).

Compound **3**: Colourless oil; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{20}$ +10.0 (*c* 0.16, CH~2~Cl~2~); IR (film) ν~max~ 3475, 2933, 1751, 1721, 1701 cm^−1^; ^1^H (500 MHz, CDCl~3~) δ 1.04 (3H, d, *J* = 6.6 Hz, H-18), 1.37 (3H, s, H-19), 1.69 (3H, s, C-17), 1.89 (2H, m, H-14), 1.92 (1H, m, H-9b), 2.27 (2H, ddd, *J* = 5.4, 9.3, 14.3 Hz, H-13a), 2.34 (1H, d, *J* = 15.1 Hz, H-9a), 2.44 (1H, m, H-2a), 2.46 (1H, m, H-2b), 2.50 (1H, m, H-13b), 2.64 (1H, ddd, *J* = 4.2, 7.1, 7.1 Hz, H-1), 2.68 (2H, m, H-7), 2.89 (1H, ddd, *J* = 6.6, 6.6, 10.6 Hz, H-4), 3.31 (1H, d, *J* = 10.4 Hz, H-5), 4.68 (1H, br s, H-16a), 4.70 (1H, br s, H-16b), 6.76 (1H, s, H-11); ^13^C NMR (125 MHz, CDCl~3~) δ 17.2 (CH~3~, C-18), 20.9 (CH~3~, C-17), 24.0 (CH~2~, C-13), 30.1 (CH~3~, C-19), 31.7 (CH~2~, C-14), 39.7 (CH, C-1), 41.9 (CH, C-4), 45.6 (CH~2~, C-9), 49.7 (CH~2~, C-2), 55.9 (CH~2~, C-7), 60.8 (CH, C-5), 74.3 (C, C-8), 90.5 (C, C-10), 109.7 (CH~2~, C-16), 131.4 (C, C-12), 149.4 (C, C-15), 155.9 (CH, C-11), 170.5 (C, C-20), 203.5 (C, C-6), 215.4 (C, C-3); EIMS *m*/*z* 362 \[M\]^+^, 347 \[M − CH~3~\]^+^, 345 \[M − OH\]^+^; HREIMS *m*/*z* \[M\]^+^ 362.1737 (calcd. for C~20~H~26~O~6~, 362.1729), \[M − CH~3~\]^+^ 347.1509 (calcd. for C~19~H~23~O~6~, 347.1495), 345.1708 (calcd. for C~20~H~25~O~5~, 345.1702).

Compound **4**: Colourless oil; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{20}$ +66.0 (*c* 0.05, CH~2~Cl~2~); IR (film) ν~max~ 3420, 2956, 1727, 1690, 1647 cm^−1^; ^1^H (500 MHz, CDCl~3~) δ 1.04 (3H, d, *J* = 6.6 Hz, H-18), 1.37 (3H, s, H-19), 1.90 (1H, dd, *J* = 2.6, 15.4 Hz H-9b), 2.00 (2H, m, H-14), 2.28 (1H, m, H-13a), 2.32 (1H, d, *J* = 15.1 Hz, H-9b), 2.49 (1H, m, H-13b), 2.53 (2H, m, H-2), 2.69 (2H, m, H-7), 2.90 (1H, m, H-1), 2.90 (1H, m, H-4), 3.31 (1H, d, *J* = 10.3 Hz, H-5), 4.03 (2H, m, H-17), 5.00 (1H, s, H-16b), 5.20 (1H, dd, *J* = 0.9, 0.9 Hz, H-16a), 6.79 (1H, s, H-11); ^13^C NMR (125 MHz, CDCl~3~) δ 17.3 (CH~3~, C-18), 22.8 (CH~2~, C-13), 30.1 (CH~3~, C-19), 31.5 (CH~2~, C-14), 35.4 (CH, C-1), 41.7 (CH, C-4), 45.6 (CH~2~, C-9), 47.6 (CH~2~, C-17), 49.9 (CH~2~, C-2), 55.9 (CH~2~, C-7), 60.9 (CH, C-5), 74.3 (C, C-8), 90.3 (C, C-10), 114.7 (CH~2~, C-16), 131.1 (C, C-12), 149.3 (C, C-15), 156.0 (CH, C-11), 171.6 (C, C-20), 205.8 (C, C-6), 215.3 (C, C-3); EIMS *m*/*z* 396/398 \[M\]^+^, 378/380 \[M − H~2~O\]^+^, 361 \[M − Cl\]^+^, 321 \[M − C~3~H~4~Cl\]^+^; HREIMS *m*/*z* \[M\]^+^ 396.1324 (calcd. for C~20~H~25~O~6~^35^Cl, 396.1340), 398.1315 (calcd. for C~20~H~25~O~6~^37^Cl, 398.1310), 361.1642 (calcd. for C~20~H~25~O~6~, 361.1651), 321.1335 (calcd. for C~17~H~21~O~6~, 321.1338).

Compound **5**: Colourless oil; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{20}$ −2.11 (*c* 0.21, CH~2~Cl~2~); IR (film) ν~max~ 2100, 1655, 1650, 1638 cm^−1^; ^1^H (500 MHz, CDCl~3~) δ 1.64 (1H, m, H-14), 1.68 (3H, s, H-17), 1.72 (1H, m, H-14), 2.16 (1H, m, H-13a), 2.21 (3H, s, H-19), 2.25 (1H, m, H-13b), 2.63 (1H, dd, *J* = 7.3, 17.7 Hz, H-9a), 2.70 (1H, m, H-1), 2.99 (1H, dd, *J* = 6.7, 17.7 Hz, H-9b), 3.12 (1H, dd, *J* = 6.6, 14.2 Hz, H-2), 3.22 (1H, dd, *J* = 8.5, 14.2 Hz, H-2), 3.86 (3H, s, H-21), 4.64 (1H, br s, H-16a), 4.73 (1H, dd, *J* = 1.6, 1.6 Hz, H-16b), 5.27 (1H, m, H-10), 7.11 (1H, m, H-11), 7.44 (1H, s, H-5), 9.54 (1H, s, H-7); ^13^C NMR (125 MHz, CDCl~3~) δ 18.0 (CH~3~, C-17), 23.1 (CH~2~, C-13), 30.1 (CH~2~, C-14), 30.5 (CH~3~, C-19), 32.3 (CH~2~, C-2), 45.7 (CH, C-1), 46.5 (CH~2~, C-9), 51.8 (CH~3~, C-21), 76.6 (CH, C-10), 113.6 (CH~2~, C-16), 116.7 (C, C-4), 122.0 (CH, C-5), 134.3 (C, C-12), 144.8 (C, C-15), 147.7 (CH, C-11), 150.6 (C, C-6), 162.9 (C, C-18), 166.6 (C, C-3), 172.9 (C, C-20), 177.1 (CH, C-7), 204.3 (C, C-8); EIMS *m*/*z* 388 \[M\]^+^, 357 \[M−OCH~3~\]^+^; ESMS *m*/*z* \[M\]^+^ 388.1524 (calcd. for C~21~H~24~O~7~, 388.1522), 357.1341 (calcd. for C~20~H~21~O~6~, 357.1338).

3.3. Activation of Pancreatic Beta-Cell Proliferation {#sec3dot3-marinedrugs-16-00049}
-----------------------------------------------------

INS-1 cells (insulinoma rat cells) were seeded at a density of 20,000 cells per well in 96-well plates. Compounds **1**, **2**, rubifolide (**7**) and scabrolide (**8**) were assayed at a final concentration of 0.1 μM in culture medium supplemented with 5.5 mM glucose. Proliferation was measured after 24 h using the BrdU kit (Roche, Mannheim, Germany), following manufacturer's instructions. At least three independent experiments in triplicate were preformed per compound.
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The following are available online at <http://www.mdpi.com/1660-3397/16/2/49/s1>, Figure S1: ^1^H NMR of **1** in CDCl~3~; Figure S2: ^13^C NMR spectrum of **1** in CDCl~3~; Figure S3: ^1^H NMR of **2** in CDCl~3~; Figure S4: ^13^C NMR spectrum of **2** in CDCl~3~; Figure S5: ^1^H NMR of **3** in CDCl~3~; Figure S6: ^13^C NMR spectrum of **3** in CDCl~3~; Figure S7: ^1^H NMR of **4** in CDCl~3~; Figure S8: ^13^C NMR spectrum of **4** in CDCl~3~; Figure S9: ^1^H NMR of **5** in CDCl~3~; Figure S10: ^13^C NMR spectrum of **5** in CDCl~3~.
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###### 

^1^H and ^13^C NMR spectroscopic data \[500 and 125 MHz, CDCl~3~\] of compounds **1** and **2**.

  -------------------------------------------------------------------------------------------------
  No.   1              2                                         
  ----- -------------- -------------------------- -------------- ----------------------------------
  1     37.6, CH       3.39, m                    39.7, CH       2.46, dddd (2.2, 2.5, 9.5, 11.7)

  2     32.9, CH~2~    3.15, m                    32.7, CH~2~    a: 2.97, dd (2.5, 14.8)\
                                                                 b: 3.19, dd (11.9, 15.1)

  3     161.3, C       \-                         162.1, C       \-

  4     123.4, C       \-                         122.7, C       \-

  5     106.5, CH      6.70, s                    106.5, CH      6.80, s

  6     156.0, C       \-                         154.3, C       \-

  7     74.0, CH       5.29, s                    75.6, CH       4.59, s

  8     74.3, C        \-                         73.6, C        \-

  9     40.5, CH~2~    1.51, m\                   43.0, CH       b: 1.89, dd (11.7, 14.8)\
                       1.87, dd (5.2, 15.0)                      a: 2.59, dd (4.2, 14.8)

  10    74.3, CH       4.85, dd (5.2, 11.3)       78.4, CH       4.97, m

  11    62.9, CH       3.73, s                    148.6, C       5.86, s

  12    60.6, C        \-                         136.2, C       \-

  13    22.5, CH~2~    a: 1.45, m\                21.7, CH~2~    a: 2.14, m\
                       b: 2.44, dd (11.5, 14.7)                  b: 2.35, ddd (2.8, 11.9, 15.1)

  14    30.4, CH~2~    1.42, m\                   30.2, CH~2~    1.60, ddd (2.8, 2.8, 15.1)\
                       2.04, m                                   2.02, m

  15    144.2, C       \-                         146.9, C       \-

  16    118.0, CH~2~   5.37, s;\                  117.0, CH~2~   5.19, s;\
                       5.47, s                                   5.36, s

  17    46.6, CH~2~    4.18, br s                 47.2, CH~2~    4.12, br s

  18    184.7, CH      9.89, s                    184.3, CH      9.97, s

  19    22.4, CH~3~    1.35, s                    19.6, CH~3~    1.41, s

  20    172.1, C       \-                         173.5, C       \-
  -------------------------------------------------------------------------------------------------

marinedrugs-16-00049-t002_Table 2

###### 

Selected ^1^H and ^13^C NMR data \[CDCl~3~\] of leptodiol, lophodiol A, **1**, sinumaximol B and **2**.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
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  --------- ------------------------------------ ------------------------------------ ---------------------- ------------------------ ------------------------
  δ~H-7~    5.12, br s                           5.24, s                              5.29, s                4.52, s                  4.59, s

  δ~H-9~    1.61, dd (8.8, 14.5)\                1.55, m\                             1.55, m\               1.85, dd (11.5, 14.5)\   1.89, dd (11.7, 14.8)\
            1.68, dd (6.9, 14.5)                 1.76, dd (6.4, 14.8)                 1.76, dd (6.4, 14.8)   2.55, dd (4.0, 14.5)     2.59, dd (4.2, 14.8)

  δ~H-19~   1.38, s                              1.40 s                               1.40, s                1.38, s                  1.41, s

  δ~C-19~   22.7                                 22.7                                 22.4                   19.8                     19.6

  δ~C-7~    73.5                                 73.4                                 74.0                   76.1                     75.6

  δ~C-9~    41.1                                 40.9                                 40.5                   43.2                     43.0
  ------------------------------------------------------------------------------------------------------------------------------------------------------------
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###### 

^1^H and ^13^C NMR Spectroscopic data \[500 and 125 MHz, CDCl~3~\] of compounds **3**, **4** and **5**.

  ----------------------------------------------------------------------------------------------------------------------------------------
  No.     3              4                                5                                                        
  ------- -------------- -------------------------------- -------------- -------------------------- -------------- -----------------------
  1       39.7 CH        2.64, ddd\                       35.4 CH        2.90, m                    45.7, CH       2.70, m
                         (4.2, 7.1, 7.1)                                                                           

  2       49.7, CH~2~    2.44, m\                         49.9, CH~2~    2.53 m\                    32.3, CH~2~    3.12, dd (6.6, 14.2)\
                         2.46, m                                         2.53, m                                   3.22, dd (8.5, 14.2)

  3       215.4, C       \-                               215.3, C       \-                         166.6, C       \-

  4       41.9, CH       2.89, ddd\                       41.7, CH       2.90, m                    116.7, C       \-
                         (6.6, 6.6, 10.6)                                                                          

  5       60.8, CH       3.31, d (10.4)                   60.9, CH       3.31, d (10.3)             122.0, CH      7.44, s

  6       203.5, C       \-                               205.8, C       \-                         150.6, C       \-

  7       55.9, CH~2~    2.68, m                          55.9, CH~2~    2.69, m                    177.1, CH      9.54, s

  8       74.3, C        \-                               74.3, C        \-                         204.3, C       \-

  9       45.6, CH~2~    b: 1.92, m\                      45.6, CH~2~    b: 1.90, dd (2.6, 15.4)\   46.5, CH~2~    2.63, dd (7.3, 17.7)\
                         a: 2.34, d (15.1)                               a: 2.32, d (15.1)                         2.99, dd (6.7, 17.7)

  10      90.5, C        \-                               90.3, C        \-                         76.6, CH       5.27, m

  11      155.9, CH      6.76, s                          156.0, CH      6.79, s                    147.7, CH      7.11, m

  12      131.4, C       \-                               131.1, C       \-                         134.3, C       \-

  13      24.0, CH~2~    a: 2.27, ddd (5.4, 9.3, 14.3)\   22.8, CH~2~    a: 2.28, m\                23.1, CH~2~    2.16, m\
                         b: 2.50, m                                      b: 2.49, m                                2.25, m

  14      31.7, CH~2~    1.89, m                          31.5, CH~2~    2.00, m                    30.1, CH~2~    1.64, m\
                                                                                                                   1.72, m

  15      149.4, CH      \-                               149.3, C       \-                         144.8, C       \-

  16      109.7, CH~2~   4.68, br s;\                     114.7, CH~2~   5.00, s;\                  113.6, CH~2~   4.64, br s\
                         4.70, br s                                      5.20, dd (0.9, 0.9)                       4.73, dd (1.6, 1.6)

  17      20.9, CH~3~    1.69, s                          47.6, CH~2~    4.03, m                    18.0, CH~3~    1.68, s

  18      17.2, CH~3~    1.04, d (6.6)                    17.3, CH~3~    1.04, d (6.6)              162.9,C        \-

  19      30.1, CH~3~    1.37, s                          30.1, CH~3~    1.37, s                    30.5, CH~3~    2.21, s

  20      170.6, C       \-                               171.6, C       \-                         172.9, C       \-

  O*Me*   \-             \-                               \-             \-                         51.8, CH~3~    3.86, s
  ----------------------------------------------------------------------------------------------------------------------------------------

marinedrugs-16-00049-t004_Table 4

###### 

Beta-cell proliferation measurement after treating INS-1 beta-cells with each compound.

  Compound (0.1 μM)      Proliferation Ratio ^a^
  ---------------------- -------------------------
  **1**                  2.5 ± 0.65
  **2**                  2.0 ± 0.61
  Rubifolide (**7**)     3.3 ± 0.80 ^b^
  Scabrolide D (**8**)   2.8 ± 0.69 ^b^

^a^ Fold change above untreated cells (1.0). A threshold over 1.5-fold was considered to increase proliferation. ^b^ *p* \< 0.05 versus control.

[^1]: Present address: University Institute of Bio-Organic Chemistry "Antonio González" (CIBICAN), University of La Laguna, 38206 Tenerife, Spain.
